These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

747 related items for PubMed ID: 27185910

  • 1. Resistance to docetaxel in prostate cancer is associated with androgen receptor activation and loss of KDM5D expression.
    Komura K, Jeong SH, Hinohara K, Qu F, Wang X, Hiraki M, Azuma H, Lee GS, Kantoff PW, Sweeney CJ.
    Proc Natl Acad Sci U S A; 2016 May 31; 113(22):6259-64. PubMed ID: 27185910
    [Abstract] [Full Text] [Related]

  • 2. Increased MYBL2 expression in aggressive hormone-sensitive prostate cancer.
    Yoshikawa Y, Stopsack KH, Wang XV, Chen YH, Mazzu YZ, Burton F, Chakraborty G, Rajanala SH, Hirani R, Nandakumar S, Lee GM, Frank D, Davicioni E, Liu G, Carducci MA, Azuma H, Kantoff PW, Sweeney CJ.
    Mol Oncol; 2022 Dec 31; 16(22):3994-4010. PubMed ID: 36087093
    [Abstract] [Full Text] [Related]

  • 3. Exploitation of the Androgen Receptor to Overcome Taxane Resistance in Advanced Prostate Cancer.
    Martin SK, Kyprianou N.
    Adv Cancer Res; 2015 Dec 31; 127():123-58. PubMed ID: 26093899
    [Abstract] [Full Text] [Related]

  • 4. Androgen receptor negatively regulates mitotic checkpoint signaling to induce docetaxel resistance in castration-resistant prostate cancer.
    Pilling A, Kim SH, Hwang C.
    Prostate; 2022 Feb 31; 82(2):182-192. PubMed ID: 34672379
    [Abstract] [Full Text] [Related]

  • 5. Interaction between docetaxel resistance and castration resistance in prostate cancer: implications of Twist1, YB-1, and androgen receptor.
    Shiota M, Kashiwagi E, Yokomizo A, Takeuchi A, Dejima T, Song Y, Tatsugami K, Inokuchi J, Uchiumi T, Naito S.
    Prostate; 2013 Sep 31; 73(12):1336-44. PubMed ID: 23775496
    [Abstract] [Full Text] [Related]

  • 6. Platelet-Synthesized Testosterone in Men with Prostate Cancer Induces Androgen Receptor Signaling.
    Zaslavsky AB, Gloeckner-Kalousek A, Adams M, Putluri N, Venghatakrishnan H, Li H, Morgan TM, Feng FY, Tewari M, Sreekumar A, Palapattu GS.
    Neoplasia; 2015 Jun 31; 17(6):490-6. PubMed ID: 26152357
    [Abstract] [Full Text] [Related]

  • 7. The pluripotency factor Nanog is directly upregulated by the androgen receptor in prostate cancer cells.
    Kregel S, Szmulewitz RZ, Vander Griend DJ.
    Prostate; 2014 Nov 31; 74(15):1530-43. PubMed ID: 25175748
    [Abstract] [Full Text] [Related]

  • 8. Reversible lysine-specific demethylase 1 antagonist HCI-2509 inhibits growth and decreases c-MYC in castration- and docetaxel-resistant prostate cancer cells.
    Gupta S, Weston A, Bearrs J, Thode T, Neiss A, Soldi R, Sharma S.
    Prostate Cancer Prostatic Dis; 2016 Dec 31; 19(4):349-357. PubMed ID: 27349498
    [Abstract] [Full Text] [Related]

  • 9. ATR inhibition controls aggressive prostate tumors deficient in Y-linked histone demethylase KDM5D.
    Komura K, Yoshikawa Y, Shimamura T, Chakraborty G, Gerke TA, Hinohara K, Chadalavada K, Jeong SH, Armenia J, Du SY, Mazzu YZ, Taniguchi K, Ibuki N, Meyer CA, Nanjangud GJ, Inamoto T, Lee GM, Mucci LA, Azuma H, Sweeney CJ, Kantoff PW.
    J Clin Invest; 2018 Jul 02; 128(7):2979-2995. PubMed ID: 29863497
    [Abstract] [Full Text] [Related]

  • 10. Identification of an anabolic selective androgen receptor modulator that actively induces death of androgen-independent prostate cancer cells.
    Schmidt A, Meissner RS, Gentile MA, Chisamore MJ, Opas EE, Scafonas A, Cusick TE, Gambone C, Pennypacker B, Hodor P, Perkins JJ, Bai C, Ferraro D, Bettoun DJ, Wilkinson HA, Alves SE, Flores O, Ray WJ.
    J Steroid Biochem Mol Biol; 2014 Sep 02; 143():29-39. PubMed ID: 24565564
    [Abstract] [Full Text] [Related]

  • 11. Sulforaphane increases the efficacy of anti-androgens by rapidly decreasing androgen receptor levels in prostate cancer cells.
    Khurana N, Talwar S, Chandra PK, Sharma P, Abdel-Mageed AB, Mondal D, Sikka SC.
    Int J Oncol; 2016 Oct 02; 49(4):1609-19. PubMed ID: 27499349
    [Abstract] [Full Text] [Related]

  • 12. Inhibition of LSD1 by Pargyline inhibited process of EMT and delayed progression of prostate cancer in vivo.
    Wang M, Liu X, Guo J, Weng X, Jiang G, Wang Z, He L.
    Biochem Biophys Res Commun; 2015 Nov 13; 467(2):310-5. PubMed ID: 26435505
    [Abstract] [Full Text] [Related]

  • 13. Histone demethylase KDM7A controls androgen receptor activity and tumor growth in prostate cancer.
    Lee KH, Hong S, Kang M, Jeong CW, Ku JH, Kim HH, Kwak C.
    Int J Cancer; 2018 Dec 01; 143(11):2849-2861. PubMed ID: 30183076
    [Abstract] [Full Text] [Related]

  • 14. Orphan nuclear receptor TLX contributes to androgen insensitivity in castration-resistant prostate cancer via its repression of androgen receptor transcription.
    Jia L, Wu D, Wang Y, You W, Wang Z, Xiao L, Cai G, Xu Z, Zou C, Wang F, Teoh JY, Ng CF, Yu S, Chan FL.
    Oncogene; 2018 Jun 01; 37(25):3340-3355. PubMed ID: 29555975
    [Abstract] [Full Text] [Related]

  • 15. Downregulation of androgen receptors by NaAsO2 via inhibition of AKT-NF-κB and HSP90 in castration resistant prostate cancer.
    Kim Y, Park SE, Moon JW, Kim BM, Kim HG, Jeong IG, Yoo S, Ahn JB, You D, Pak JH, Kim S, Hwang JJ, Kim CS.
    Prostate; 2017 Jul 01; 77(10):1128-1136. PubMed ID: 28556958
    [Abstract] [Full Text] [Related]

  • 16. Inhibition of Hsp90 augments docetaxel therapy in castrate resistant prostate cancer.
    Ku S, Lasorsa E, Adelaiye R, Ramakrishnan S, Ellis L, Pili R.
    PLoS One; 2014 Jul 01; 9(7):e103680. PubMed ID: 25072314
    [Abstract] [Full Text] [Related]

  • 17. Low β₂-adrenergic receptor level may promote development of castration resistant prostate cancer and altered steroid metabolism.
    Braadland PR, Grytli HH, Ramberg H, Katz B, Kellman R, Gauthier-Landry L, Fazli L, Krobert KA, Wang W, Levy FO, Bjartell A, Berge V, Rennie PS, Mellgren G, Mælandsmo GM, Svindland A, Barbier O, Taskén KA.
    Oncotarget; 2016 Jan 12; 7(2):1878-94. PubMed ID: 26646591
    [Abstract] [Full Text] [Related]

  • 18. Differential regulation of metabolic pathways by androgen receptor (AR) and its constitutively active splice variant, AR-V7, in prostate cancer cells.
    Shafi AA, Putluri V, Arnold JM, Tsouko E, Maity S, Roberts JM, Coarfa C, Frigo DE, Putluri N, Sreekumar A, Weigel NL.
    Oncotarget; 2015 Oct 13; 6(31):31997-2012. PubMed ID: 26378018
    [Abstract] [Full Text] [Related]

  • 19. Intracrine androgen biosynthesis in renal cell carcinoma.
    Lee GT, Han CS, Kwon YS, Patel R, Modi PK, Kwon SJ, Faiena I, Patel N, Singer EA, Ahn HJ, Kim WJ, Kim IY.
    Br J Cancer; 2017 Mar 28; 116(7):937-943. PubMed ID: 28253524
    [Abstract] [Full Text] [Related]

  • 20. Combination treatment with docetaxel and histone deacetylase inhibitors downregulates androgen receptor signaling in castration-resistant prostate cancer.
    Park SE, Kim HG, Kim DE, Jung YJ, Kim Y, Jeong SY, Choi EK, Hwang JJ, Kim CS.
    Invest New Drugs; 2018 Apr 28; 36(2):195-205. PubMed ID: 29110173
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 38.